WallStreetZenWallStreetZen

NASDAQ: ADRX
Adarx Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ADRX

Based on 3 analysts offering 12 month price targets for Adarx Pharmaceuticals Inc

Min Forecast
$32.00+114.62%
Avg Forecast
$35.00+134.74%
Max Forecast
$38.00+154.86%

Should I buy or sell ADRX stock?

Based on 4 analysts offering ratings for Adarx Pharmaceuticals Inc.

Strong Buy
Strong Buy
4 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ADRX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ADRX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their ADRX stock forecasts and price targets.

ADRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-20
lockedlocked$00.00+00.00%2026-10-20
lockedlocked$00.00+00.00%2026-10-20
lockedlocked$00.00+00.00%2026-10-20

1 of 1

Forecast return on equity

Is ADRX forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is ADRX forecast to generate an efficient return on assets?

Company
-41.3%
Industry
-2.99%
ADRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ADRX earnings per share forecast

What is ADRX's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$1.92
Avg 2 year Forecast
-$1.65
Avg 3 year Forecast
-$1.84

ADRX revenue forecast

What is ADRX's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$6.2M
Avg 2 year Forecast
$40.6M
Avg 3 year Forecast
$40.5M

ADRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACRV$1.46N/AN/A
ABVX$90.20$154.55+71.34%Strong Buy
ADMA$13.24$15.00+13.29%Buy
ADXN$5.29N/AN/A
ABUS$4.03N/AN/A
View Top Biotech Stocks

Adarx Pharmaceuticals Stock Forecast FAQ

Is Adarx Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: ADRX) stock is to Strong Buy ADRX stock.

Out of 4 analysts, 4 (100%) are recommending ADRX as a Strong Buy, 0 (0%) are recommending ADRX as a Buy, 0 (0%) are recommending ADRX as a Hold, 0 (0%) are recommending ADRX as a Sell, and 0 (0%) are recommending ADRX as a Strong Sell.

If you're new to stock investing, here's how to buy Adarx Pharmaceuticals stock.

What is ADRX's earnings growth forecast for 2026-2028?

(NASDAQ: ADRX) Adarx Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.63%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 70.08%.

Adarx Pharmaceuticals's earnings in 2026 is N/A.On average, 7 Wall Street analysts forecast ADRX's earnings for 2026 to be -$196,184,857, with the lowest ADRX earnings forecast at -$260,407,906, and the highest ADRX earnings forecast at -$166,331,973. On average, 7 Wall Street analysts forecast ADRX's earnings for 2027 to be -$168,253,350, with the lowest ADRX earnings forecast at -$183,287,103, and the highest ADRX earnings forecast at -$126,626,921.

In 2028, ADRX is forecast to generate -$188,478,909 in earnings, with the lowest earnings forecast at -$215,337,307 and the highest earnings forecast at -$168,478,192.

What is ADRX's revenue growth forecast for 2026-2028?

(NASDAQ: ADRX) Adarx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 42.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.94%.

Adarx Pharmaceuticals's revenue in 2026 is N/A.On average, 7 Wall Street analysts forecast ADRX's revenue for 2026 to be $628,944,369, with the lowest ADRX revenue forecast at $289,024,159, and the highest ADRX revenue forecast at $1,824,286,154. On average, 7 Wall Street analysts forecast ADRX's revenue for 2027 to be $4,148,947,939, with the lowest ADRX revenue forecast at $0, and the highest ADRX revenue forecast at $8,799,497,921.

In 2028, ADRX is forecast to generate $4,143,735,693 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $6,841,124,179.

What is ADRX's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: ADRX) forecast ROA is -41.3%, which is lower than the forecast US Biotechnology industry average of -2.99%.

What is ADRX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ADRX price target, the average ADRX price target is $35.00, with the highest ADRX stock price forecast at $38.00 and the lowest ADRX stock price forecast at $32.00.

On average, Wall Street analysts predict that Adarx Pharmaceuticals's share price could reach $35.00 by Oct 20, 2027. The average Adarx Pharmaceuticals stock price prediction forecasts a potential upside of 134.74% from the current ADRX share price of $14.91.

What is ADRX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ADRX) Adarx Pharmaceuticals's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that ADRX's EPS will be -$1.92 for 2026, with the lowest EPS forecast at -$2.55, and the highest EPS forecast at -$1.63. On average, analysts forecast that ADRX's EPS will be -$1.65 for 2027, with the lowest EPS forecast at -$1.79, and the highest EPS forecast at -$1.24. In 2028, ADRX's EPS is forecast to hit -$1.84 (min: -$2.11, max: -$1.65).

What is ADRX's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: ADRX) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.